Group 1 - The company, Guoshengtang (02273.HK), announced a share buyback on December 10, spending HKD 4.263 million to repurchase 150,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年12月10日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括 ...

Core Insights - The integration of technology and traditional Chinese medicine (TCM) is gaining momentum, with significant developments in AI applications within the industry [1][2] - Guoshengtang is positioning itself as a leader in TCM modernization and internationalization, aiming to enhance the quality and accessibility of TCM resources [1][3] Group 1: AI and Technology Integration - Guoshengtang has established strategic partnerships with top research teams to develop TCM-specific AI models, marking a shift from exploration to large-scale application [2][3] - The AI platform, "Guoyi AI Avatar," has achieved an expert simulation consistency of over 86%, enhancing the efficiency of online consultations and addressing the uneven distribution of quality medical resources [3][4] - The company has been building a digital infrastructure since 2019, accumulating extensive clinical data to support its AI initiatives [2][3] Group 2: Clinical Research and Evidence-Based Medicine - The launch of the "Xunyan Zhizhi" clinical research integration platform aims to address the challenges of evidence-based evaluation in TCM, utilizing AI to create a comprehensive innovation system [6][7] - This platform will facilitate the collection of accurate clinical data, enabling objective assessments of TCM efficacy and promoting a shift from experience-based to evidence-based medicine [6][7] Group 3: Global Expansion and Market Strategy - Guoshengtang is expanding its global footprint through a "merger + cooperation + self-built" strategy, with plans to acquire 14 clinics in Singapore and establish a joint venture with a digital healthcare platform [9][10] - The company has formed strategic partnerships with various platforms to enhance its service accessibility and user engagement, significantly increasing its customer acquisition rates [8][9] - By 2026, Guoshengtang plans to enter markets in Hong Kong and Malaysia, followed by expansion into Europe and the United States [1][9]

固生堂回购明细 | 日期 | 回购股数 | 回购最高价 | 回购最低价 | 回购金额 | | --- | --- | --- | --- | --- | | | （万股） | （港元） | （港元） | （万港元） | | 2025.12.09 | 34.01 | 28.400 | 28.020 | 959.73 | | 2025.12.08 | 22.06 | 28.480 | 27.860 | 622.16 | | 2025.12.05 | 18.60 | 28.460 | 28.460 | 529.36 | | 2025.12.04 | 20.00 | 28.680 | 28.420 | 571.93 | | 2025.12.03 | 32.00 | 28.980 | 28.520 | 919.33 | | 2025.12.02 | 37.84 | 29.380 | 28.700 | 1094.52 | | 2025.11.28 | 28.76 | 30.000 | 29.620 | 858.54 | | 2025.11.27 | 30.91 | 29.920 | 29.440 | 920.00 | | ...

Core Viewpoint - The collaboration between Guoshengtang and four top research teams aims to develop a robust Traditional Chinese Medicine (TCM) AI model and intelligent systems, enhancing the supply of quality TCM services and accelerating the training of young physicians [1][3]. Group 1: Collaboration and Technological Foundation - Guoshengtang has partnered with four leading research teams, each a recognized authority in their fields, to create a comprehensive technical support system for TCM AI model development [4]. - The collaboration focuses on five key breakthroughs, including the creation of an industry-leading TCM AI model base that enhances clinical practicality and reliability [4]. - A comprehensive evaluation system for TCM AI models will be established in collaboration with authoritative institutions to ensure fair assessment and continuous optimization of model performance [4]. Group 2: AI Applications and Innovations - The "National Medicine AI Avatar" product, specifically the "TCM Brain," has been launched to provide real-time clinical decision support to young physicians, marking a significant advancement in empowering medical professionals [6][8]. - The TCM Brain integrates with Guoshengtang's HIS system to create a full-process assistance system, improving the efficiency of diagnosis and treatment documentation [8]. - The AI system is designed to provide evidence-based recommendations, allowing young physicians to learn from expert diagnostic reasoning, thereby shortening their training period and enhancing the standardization of treatment [8][9]. Group 3: Resource Optimization and Future Plans - Guoshengtang has established a dedicated AI team and is systematically developing AI capabilities, including hardware and data collection, to ensure a complete research and implementation chain [10]. - The company plans to launch an expert AI studio to further enhance the value of quality TCM resources and address core industry challenges such as resource scarcity and long training cycles for physicians [11].

Group 1 - The company, Guoshengtang (02273.HK), announced a share buyback on December 9, spending HKD 9.597 million to repurchase 340,000 shares [1] - The buyback reflects the company's strategy to enhance shareholder value amidst its ongoing initiatives in traditional Chinese medicine and AI technology [1] - Guoshengtang is focusing on both technological advancements and global expansion to drive new growth momentum [1]

智通财经APP讯，固生堂(02273)发布公告，于2025年12月9日该公司斥资959.73万港元回购34.01万股， 回购价格为每股28.02-28.40港元。 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 固生堂控股有限公司 呈交日期： 2025年12月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02273 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已 ...

Core Insights - The conference held by Gushengtang on December 5, 2025, showcased significant collaborations and achievements in the integration of traditional Chinese medicine (TCM) and artificial intelligence (AI), highlighting the company's commitment to modernizing TCM and expanding its international presence [1][3]. Group 1: AI Model Development - Gushengtang announced partnerships with four leading research teams to develop a TCM AI model, enhancing clinical applicability and reliability through interdisciplinary collaboration [7][8]. - The collaboration aims to create a robust AI evaluation system and develop AI applications like the "National Medicine AI Avatar" to assist in diagnosis and patient management [8][9]. Group 2: Clinical Research Integration - A clinical research integration platform was launched to accelerate the transformation of clinical research outcomes, focusing on real-world data evaluation in TCM [10]. - Gushengtang has completed 16 internal formulations, with one product successfully certified and launched in Singapore, demonstrating its strong R&D capabilities [10]. Group 3: Global Expansion and Ecosystem Development - Gushengtang is expanding its service boundaries through a strategic partnership with Amap, integrating TCM services with navigation and local life scenarios to enhance user accessibility [11]. - The company is adopting a "merger + cooperation + self-built" strategy for global expansion, with a full acquisition of Singapore Chinese Medicine to increase its presence in the region [12].

Core Insights - The conference held by Guoshengtang on December 5, 2025, showcased significant collaborations and innovations in the integration of traditional Chinese medicine (TCM) and artificial intelligence (AI) [1][3] - Guoshengtang aims to modernize and internationalize TCM, responding to national policy initiatives and expanding its service capabilities through AI and overseas market development [3] Group 1: Collaborations and Innovations - Guoshengtang announced partnerships with four leading research teams to develop a TCM AI model, enhancing clinical applicability and reliability [6] - The company launched the "National Medicine AI Avatar" product, providing real-time clinical decision support for young doctors, currently in trial operation across several specialties [7] - A clinical research integration platform was initiated to address real-world data evaluation challenges in TCM, with 16 internal formulations already registered [8] Group 2: Global Expansion and Market Strategy - Guoshengtang signed a strategic cooperation agreement with Amap to integrate TCM services with navigation and local life scenarios, enhancing user accessibility [10] - The company is pursuing a "merger + cooperation + self-built" strategy for global expansion, with a full acquisition of Singapore Chinese Medicine to increase its presence in the region [10] - The overall strategy emphasizes AI-driven diagnosis, research-driven products, and a comprehensive flow ecosystem to support TCM's international outreach [10]